期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性便秘治疗药物的研究进展 被引量：10

Research progress on drugs in treatment of chronic constipation
原文传递
导出
摘要 慢性便秘是一种常见疾病,能够明显影响患者的生活质量,并且需要投入大量治疗费用。用于治疗慢性便秘的药物种类较多,包括促动力药、促分泌药、胆汁酸调节剂和缓泻剂等药物,但是目前没有一种药物能够治疗所有类型的慢性便秘。按照相关作用机制,介绍了一些临床使用或在研的慢性便秘的治疗药物。 Chronic constipation is a common health problem that significantly affects the quality of life of patients, and needs a lot of treatment costs. Although there are many drugs in treatment of chronic constipation, such as prokinetics, pancreotropics, bile acid modulators, and laxatives, etc. Yet there is still no an ideal drug that might be useful in all cases. This paper presents a number of chemical drugs in the clinical use or developing in accordance with the mechanism of chronic constipation.
作者 崔金国
机构地区 天津市宝坻区人民医院药剂科
出处 《现代药物与临床》 CAS 2016年第4期557-561,共5页 Drugs & Clinic
关键词 慢性便秘 治疗药物 研究进展 chronic constipation therapeutic drugs research progress
分类号 R983 [医药卫生—药品]
  • 相关文献

参考文献34

  • 1Higgins P D, Johanson J F. Epidemiology of constipation in North America: a systematic review [J]. Am J Gastroenterol, 2004, 99(4): 750-759.
  • 2Wald A, Scarpignato C, Mueller-Lissner S, et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation [J]. Aliment Pharmacol Ther, 2008, 28(7): 917-930.
  • 3Crowell M D, Shetzline M A, Moses P L, et al. Enterochromaffm cells and 5-HT signaling in the pathophysiology of disorders of gastrointestinal function [J]. Curr Opin Investig Drugs, 2004, 5(1): 55-60.
  • 4De Maeyer J H," Lefebvre R A, Schuurkes J A. 5-HT4 receptor agonists: similar but not the same [J]. Neurogastroenterol Motil, 2008, 20(2): 99-112.
  • 5Gershon M D, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders [J]. Gastroenterology, 2007, 132(1): 397-414.
  • 6Briejers M R, Bosmans J P, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound [J]. Eur J Pharmacol, 2001, 423(1): 71-83.
  • 7Camilleri M, Kerstens R, Rykx A, et al. A placebo- controlled trial of pmcalopride for severe chronic constipation [J]. NEnglJMed, 2008, 358(22): 2344-2354.
  • 8Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives [J]. Gut, 2009, 58(3): 357-365.
  • 9Quigley E M, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of pmcalopride in severe chronic constipation a 12-week, randomized, double-blind, placebo-controlled study [J]. Aliment Pharmacol Ther, 2009, 29(3): 315-328.
  • 10Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a doubleblind, placebo-controlled study [J]. NeurogastroenterolMotil, 2009, 21(12): 1256-e117.

二级参考文献11

  • 1Zhao YF, Ma XQ, Wang R, et al. Epidemiology of functional constipation and comparison with constipation- predominant irritable bowel syndrome:the Systematic Investigation of Gastrointestinal Diseases in China (SILC). Aliment Pharmacol Ther, 2011,34 : 1020-1029.
  • 2Jones MP, Talley NJ, Nuyts G, et al. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci, 2002,47:2222-2230.
  • 3Wald A, Scarpignato C, Mueller-Lissner S, et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther, 2008,28 :917-930.
  • 4Emmanuel AV, Roy AJ, Nicholls TJ, et al. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmaeol Ther, 2002,16:1347-1356.
  • 5Camilleri M, Kerstens R, Rykx A, et al. A placebo- controlled trial of pruealopride for severe chronic constipation. N Engl J Med, 2008,358:2344-2354.
  • 6Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of pruealopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther, 2009,29 : 315-328.
  • 7Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut, 2009,58:357-365.
  • 8Frank L, Kleinman L, Farup C, et al. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol, 1999,34:870-877.
  • 9Marquis P, De La Loge C, Dubois D,et al. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Stand J Gastroenterol, 2005, 40: 540-551.
  • 10Corazziari E, Bytzer P, Delvaux M, et al. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther, 2003,18 : 569-580.

共引文献30

同被引文献118

引证文献10

二级引证文献56

现代药物与临床
2016年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部